CMTHIGH SIGNALFINANCIAL10-K

CMT delivered exceptional financial performance with revenue surging 281% to $284.3M and net income jumping 496% to $11.2M, representing a dramatic business transformation.

This represents a fundamental shift in CMT's business scale and profitability, with revenue nearly tripling while maintaining strong margin expansion. The company appears to have executed a successful growth strategy, though the sustainability of these gains and underlying drivers require careful monitoring given the magnitude of change.

Comparing 2026-03-10 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

CMT experienced explosive growth across all revenue metrics, with gross profit expanding 369% and operating income rising 453%, indicating both volume growth and improved operational efficiency. However, operating cash flow declined 45% to $19.2M despite the earnings surge, suggesting potential working capital pressures or timing differences that warrant scrutiny. The company reduced debt by 11% while increasing capital expenditures by 50% to support growth, demonstrating disciplined capital allocation amid rapid expansion.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+496.4%
$1.9M$11.2M

Net income grew 496.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+452.6%
$2.6M$14.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Gross Profit
P&L
+369%
$10.1M$47.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+280.8%
$74.7M$284.3M

Strong top-line growth of 280.8% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
+100.5%
-$193K$1K

Interest expense surged 100.5% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
+49.8%
$11.5M$17.3M

Capital expenditure jumped 49.8% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-45.4%
$35.2M$19.2M

Operating cash flow fell 45.4% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
-26.3%
$1.9M$1.4M

R&D spending cut 26.3% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
+12.5%
$62.2M$70.0M

Liabilities increased 12.5% — monitor debt-to-equity ratio and interest coverage.

Total Debt
Balance Sheet
-10.5%
$19.7M$17.6M

Debt reduced 10.5% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-11
ADDED
As of March 9, 2026, the latest practicable date, 8,833,231 shares of the registrant s common stock were issued, which includes 338,554 shares of unvested restricted common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 7A.
As of December 31, 2025, the Company owned 82 molding presses including 18 in its Columbus, Ohio facility; 25 in its Matamoros, Mexico facility; 18 in its Cobourg, Canada facility; 10 in its Gaffney, South Carolina facility; 5 in its Winona, Minnesota facility; and 6 in its Monterrey, Mexico facility.
CAPITAL EXPENDITURES AND RESEARCH AND DEVELOPMENT Capital expenditures totaled approximately $17.3 million, $11.5 million, and $9.1 million in 2025, 2024, and 2023, respectively.
Management has estimated that costs related to research and development were approximately $1.4 million, $1.9 million and $1.7 million in 2025, 2024, and 2023, respectively.
+7 more — sign up free →
REMOVED
As of March 11, 2025, the latest practicable date, 8,895,735 shares of the registrant s common stock were issued, which includes 281,340 shares of unvested restricted common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.
As of December 31, 2024, the Company owned 82 molding presses including 19 in its Columbus, Ohio facility; 24 in its Matamoros, Mexico facility; 18 in its Cobourg, Canada facility; 10 in its Gaffney, South Carolina facility; 5 in its Winona, Minnesota facility; and 6 in its Escobedo, Mexico facility.
CAPITAL EXPENDITURES AND RESEARCH AND DEVELOPMENT Capital expenditures totaled approximately $11.5 million, $9.1 million, and $16.6 million in 2024, 2023, and 2022 respectively.
Management has estimated that costs related to research and development were approximately $1.9 million, $1.7 million and $1.6 million in 2024, 2023, and 2022, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →